Bergen, Norway, 6 June 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, is pleased to announce presentation of a poster at the ASCO
Annual Meeting to be held from 3rd - 8th June 2022.

The poster presentation provides clinical data from a Phase 1 dose escalation
and expansion study of bemcentinib (BGB324) in combination with docetaxel in
patients with previously treated advanced non-small cell lung cancer (NSCLC).
The data presented indicate that bemcentinib in combination with docetaxel shows
evidence of anti-tumor activity, with 35% of patients achieving a partial
response and 47% attaining stable disease, and a manageable safety profile in
previously treated, advanced NSCLC.

Cristina Oliva, Chief Medical Officer at BerGenBio, commented: "While the data
are limited, they suggest a mechanism by which treatment with bemcentinib could
delay resistance to and potentiate the effects of chemotherapy treatment in
NSCLC patients."

The full abstract is available on the ASCO website here:
https://meetings.asco.org/abstracts-presentations/212839

Full details of the presentation are below:

Title:Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a
first-in-class, selective AXL inhibitor, with docetaxel in patients with
previously treated advanced NSCLC.

Author:Bhalla et al.

Session/Abstract ID:Lung Cancer - Non Small Cell Metastatic / 9081

Location/Time:  June 6, 2022, Hall D1, 1:25pm Central Time

Contacts:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on
developing transformative drugs targeting AXL as a potential cornerstone of
therapy for aggressive diseases, including cancer and severe respiratory
infections. The Company is focused on its proprietary lead candidate bemcentinib
a potentiallyfirst-in-class selective AXL inhibitor in development for STK11
mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.